Related Experiment Videos
Adapalene, a new chemical entity with retinoid activity
1Centre International de Recherches Dermatologiques, GALDERMA, Sophia Antipolis, France.
Skin Pharmacology : the Official Journal of the Skin Pharmacology Society
|January 1, 1993
Summary
Adapalene, a novel acne treatment, offers comparable or superior efficacy to tretinoin with better tolerability. Its unique pharmacological profile suggests it targets epidermal cell differentiation, providing a beneficial option for acne vulgaris management.
Area of Science:
- Dermatology and Pharmacology
- Retinoid Receptor Modulation
Background:
- Adapalene is a novel chemical entity with pharmacological properties similar to tretinoin.
- It exhibits unique selectivity for nuclear retinoic acid receptors (RARs) and lacks transactivating potential for RXR alpha.
Purpose of the Study:
- To evaluate the pharmacological profile and clinical efficacy of adapalene.
- To compare adapalene's anti-acne effects and tolerability against tretinoin.
Main Methods:
- Pharmacological assessment of retinoic acid receptor binding and transactivation.
- In vitro and in vivo anti-inflammatory and comedolytic activity testing.
- Comparative clinical study in 72 acne patients versus tretinoin.
Main Results:
- Adapalene demonstrated selective RAR binding and affected epidermal cell differentiation.
- It exhibited comedolytic and anti-inflammatory effects in preclinical models.
- Clinical studies showed adapalene's efficacy comparable or superior to tretinoin with improved tolerability.
Conclusions:
- Adapalene's unique receptor profile may influence epidermal differentiation pathways.
- It possesses significant anti-inflammatory and comedolytic properties.
- Adapalene is a well-tolerated and effective treatment option for acne vulgaris.